How to Test for Mold Toxicity: What a Panel Can Prove

No blood or urine test currently proves mold made you sick: urine mycotoxin panels have no FDA-approved version, no healthy reference distribution and no validated cutoff. What can be established is your exposure history, the building’s damage and the measurable state of your own physiology.

A mold panel feels like an answer because it prints a number. Before you buy one, look at what stands under that number, and at which measurements in your own body can actually move a plan.

People asking how to test for mold toxicity are usually one click from a shopping cart: a urine panel, a marker set, a protocol sold as one package. Hold that click, because any test worth paying for has to clear three bars. It measures something real. It has a distribution of healthy, unexposed people standing under its numbers. And the answer changes what happens next. The chapter video, Mold Illness: Fix the Basement, Skip the Panel, grades the mold claims tier by tier. What follows sorts the measurements by those three bars.

The compounds are real, and that is not the argument

Start where nobody disputes anything. Aflatoxin, a mold toxin that grows on stored crops, is classified as carcinogenic to humans and causes liver cancer. That burden sits mostly in sub-Saharan Africa, Southeast Asia and China, where largely uncontrolled contamination of food meets high rates of hepatitis B. Name the population, because the population is the whole meaning of the number. A Midwestern basement is not that population.

Milder compounds, meanwhile, are in nearly everyone. Fifty pregnant American women were sampled at four separate points, blood and urine both. One grain toxin, deoxynivalenol, turned up in 99% of their urine samples at a median of 23 ng/mL. The carcinogenic aflatoxins were not detected in any sample at all. So a laboratory finding a mycotoxin in you has proved only that you eat food. That is why the interesting question was never presence but amount, and amount is where a panel goes quiet.

Amount can be measured, just not by the panels sold for it. In that same group of women, estimated intake ran over the tolerable daily limit for deoxynivalenol at 28% of the measurements on average and for zearalenone at 2%. Judged against the stricter human biomonitoring guidance value, the deoxynivalenol figure averaged 48%. Every sample with a quantified ochratoxin A level carried a margin of exposure under 10,000, which regulators treat as a flag for possible concern. Food was the route in that study. Not one damp basement was in it.

Why a urine mycotoxin panel cannot come back positive

Mycotoxin and urine panels are not Measura [Cardiometabolic and Autonomic Health Analysis] tests. They are different tests, ordered from outside laboratories, and the reason to know that is not modesty about the menu. No urine mycotoxin assay has FDA approval. Traces sit in everyday groceries, so healthy people excrete them too. The lab regulations governing these panels never ask whether the assay measures the thing it claims to measure.

One federal case report shows what that does to a family. The panel returned ochratoxin at 2.8 parts per billion where the laboratory drew its positive line at 2.0, and trichothecenes at 0.4 where that line sat at 0.2. Each compound carries its own threshold, and each result landed above its own. The panel was positive twice over on its own terms. Investigators then pulled out drywall, carpet and ceiling tiles, and found neither water damage nor significant fungal growth. Without a validated threshold, a number cannot be positive. It can only be higher than a line somebody chose.

What a damp building is proven to do

The building evidence is stronger than the blood work, and it is graded honestly by the people who wrote it. The 2004 American synthesis found sufficient evidence linking damp indoor spaces to some upper respiratory symptoms. A 2024 European guideline sorts the outcomes into tiers: respiratory disease sufficient, atopic eczema limited or suspected, gastrointestinal effects inadequate or insufficient. The gut itself, the first brain, sits in the weakest tier of the best document in the field, and pretending otherwise would make everything else here worth less.

Scale matters too. Sensitization to mold across the general European population runs 3% to 22.5%, and about 5% of people are predicted to develop some allergic airway symptoms from molds over a lifetime, mostly from outdoor rather than indoor species. Outside the chest, the measured signal is old and blunt: across 597 households in 1989, adults in damp, moldy homes described more symptoms, including nausea and vomiting; the count climbed as the damp got worse, and the pattern survived adjustment for smoking, unemployment and overcrowding.

The repair with the cleanest human data

Pooled trials of repairing damp, moldy houses lowered the odds of adult wheezing to 0.64 and of rhinitis to 0.57, on moderate-quality evidence. In children, asthma days did not move against information alone, and no included study measured a gut outcome at all. Even the occupational medicine paper that flatly rejects the diagnosis agrees that mold growth at home, school or work should not be tolerated.

Notice who pays. Drying a foundation properly is expensive and slow, ignoring it costs nothing today, and the person who signs for the work is rarely the person sleeping above it. A panel, by contrast, can be sold to the tenant tonight. Follow the invoice and you can predict which claim gets marketed and which repair gets postponed another winter.

How to test for mold toxicity in the body while the wall dries

A stall in recovery deserves a second explanation, not just a louder version of the first one. Two biological drivers sit under most of these stories. The intestinal barrier is one: mycotoxins degrade its physical, mucus, immune and microbial layers, though that work is built in cells and animals rather than people. The immune system is the other, where asthma, allergic rhinitis, sinusitis and hypersensitivity pneumonitis are well defined while the newer mold illnesses remain largely unproved.

Both of those are more measurable as terrain than as toxin. Laboratory panels can put metabolic and inflammatory markers on a page for your physician, which is how metaflammation and insulin resistance stop being adjectives. Autonomic nervous system testing measures how your nerves regulate heart rate, blood pressure and sweating, which is the machinery behind feeling wiped out and unsteady on standing. Cognitive assessment records where your thinking sits today, and that is a baseline rather than a verdict about mold; American toxicology states there is no documented evidence that inhaled indoor fungi cause a chronic toxic encephalopathy. Measura measures and reports. Your physician decides what any finding means and what to do.

Then keep the instrument you already own. Keep a dated log instead of a memory: the day symptoms changed, the address you woke up at, and anything that happened to the house beforehand. Pollen does the same away-better, home-worse trick on a seasonal calendar, so dates are what separate the two. Sleep, food and movement have more room to work once an exposure is gone, which is the physiological reason the repair comes before the rebuild. Nothing here is a reason to start, stop or change a medication. The graded studies, with their full numbers and their limits, are in the chapter companion, and the barrier argument has its own measurement story.

Frequently asked questions

Is there a blood or urine test that proves mold made me sick?

No test currently does that. Urine mycotoxin panels have no FDA-approved version, no healthy reference distribution and no validated cutoff, and European and American specialty bodies both call them unsuitable for clinical diagnosis. Antibody versions are rejected as well. What can be established is exposure history and building damage, plus the measurable state of your own physiology. What a result can and cannot tell you sets the standard these panels miss.

Why did my panel come back positive if the compounds are in everyone?

Because positive on those reports means above a line the laboratory picked, not above a distribution measured in well people. Low levels ride in ordinary groceries and therefore in ordinary urine. In the detailed federal case, two compounds cleared their own cutoffs and the building turned out to be sound after destructive inspection. Ask what a positive would change before ordering one. Questions worth asking your doctor covers that conversation.

I feel better away from home. Does that mean it is the house?

It means you have the most useful observation available, and it deserves to be recorded properly rather than argued about. Log dates, addresses and what changed in the building beforehand, because seasonal pollen produces the same pattern on a different calendar. Bring the log to your physician as data, not as a theory. Understanding your results explains how findings and history get read together.

Should I have remediation done before any testing?

Repairing a damp building is the intervention with real human outcome data behind it, and adult airways measurably improve after it. No trial has measured a gut outcome after remediation, so that part rests on mechanism and on a precaution every guideline shares. Repair is also not a purchase anybody can sell you twice. What Measura actually measures shows what sits outside that work.

What does the physician version of this question look like?

Shorter and colder: who to screen, which findings alter management, and how to document a stalled recovery without ordering an unvalidated assay. The clinical framing also covers the marker set sold beside these panels and why it stands neither confirmed nor refuted outside one group. The screening view of the same evidence is written for that reader.

Measure the terrain, not the rumor

Ask about metabolic, autonomic and cognitive measurement so your physician has real numbers for a recovery that stalled. Findings go to your physician, who decides what changes.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

International Agency for Research on Cancer. (2012). Aflatoxins. In: Chemical agents and related occupations (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100F). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 100F, Aflatoxins monograph, Evaluation section. https://www.ncbi.nlm.nih.gov/books/NBK304413/
Krausová, M., Ayeni, K. I., Gu, Y., Borutzki, Y., O’Bryan, J., Perley, L., Silasi, M., Wisgrill, L., Johnson, C. H., & Warth, B. (2024). Longitudinal biomonitoring of mycotoxin exposure during pregnancy in the Yale Pregnancy Outcome Prediction Study. Environment International, 194, 109081. https://doi.org/10.1016/j.envint.2024.109081
Kawamoto, M., & Page, E. (2015). Notes from the field: Use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness — United States, 2014. MMWR. Morbidity and Mortality Weekly Report, 64(6), 157-158. https://pubmed.ncbi.nlm.nih.gov/25695323/
Hurraß, J., Heinzow, B., Walser-Reichenbach, S., Aurbach, U., Becker, S., Bellmann, R., Bergmann, K.-C., Cornely, O. A., Engelhart, S., Fischer, G., Gabrio, T., Herr, C. E. W., Joest, M., Karagiannidis, C., Klimek, L., Köberle, M., Kolk, A., Lichtnecker, H., Lob-Corzilius, T., … Wiesmüller, G. A. (2024). AWMF mold guideline “Medical clinical diagnostics for indoor mold exposure” – Update 2023 AWMF Register No. 161/001. Allergologie Select, 8, 90-198. https://doi.org/10.5414/ALX02444E
Platt, S. D., Martin, C. J., Hunt, S. M., & Lewis, C. W. (1989). Damp housing, mould growth, and symptomatic health state. BMJ (Clinical Research Ed.), 298(6689), 1673-1678. https://doi.org/10.1136/bmj.298.6689.1673
Sauni, R., Verbeek, J. H., Uitti, J., Jauhiainen, M., Kreiss, K., & Sigsgaard, T. (2015). Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. Cochrane Database of Systematic Reviews, 2015(2), CD007897. https://doi.org/10.1002/14651858.CD007897.pub3
Hardin, B. D., Kelman, B. J., & Saxon, A. (2003). Adverse human health effects associated with molds in the indoor environment. Journal of Occupational and Environmental Medicine, 45(5), 470-478. https://doi.org/10.1097/00043764-200305000-00006
Leikin, J., Holland, M. G., Kurt, T. L., McKay, C. A., & Stolbach, A. I. (American College of Medical Toxicology). (2025). ACMT position statement: Medical toxicology considerations in the diagnosis and treatment of patients with concerns about mold-related inhalation exposures. https://www.acmt.net/wp-content/uploads/2025/08/PS_250813_ACMT-Position-Statement-Mold-Related-Inhalation-Exposures.pdf
Gao, Y., Meng, L., Liu, H., Wang, J., & Zheng, N. (2020). The compromised intestinal barrier induced by mycotoxins. Toxins, 12(10), 619. https://doi.org/10.3390/toxins12100619